Alnylam Pharmaceuticals Inc annual ebitda for fiscal TTM was $924 million, an increase of 46.4% from $631 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | $924M | $631M | ($179M) | ($258M) | ($927M) | ($662M) | ($736M) | ($885M) | ($754M) | ($487M) | ($409M) | ($277M) | ($172M) | ($83M) | ($52M) | ($50M) | ($38M) | ($41M) | ($19M) | ($75M) | ($36M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| EBITDA | $304M | $304M | $297M | $19M | $11M | ($141M) | ($60M) | $37M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More ALNY metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All ALNY financial statements → Interactive ALNY charts →
About TickerBase · Data methodology & sources